MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa – Nasdaq

MANF Therapeutics Receives Notice of Allowance from US Patent & Trademark Office Covering the Use of MANF or CDNF as a Treatment for Glaucoma, Macular Degeneration and Retinitis Pigmentosa  Nasdaq

New York, NY, Jan. 15, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — MANF Therapeutics, a wholly-owned subsidiary of Amarantus Bioscience …